약물 남용 검사 시장 : 검체 유형별, 검사 기술, 검사 대상 약물, 최종 사용자별 예측(2026-2032년)

The Drug of Abuse Testing Market is projected to grow by USD 10.12 billion at a CAGR of 8.06% by 2032.

Drug of Abuse Testing Market Introduction

Drug of abuse testing is becoming a core risk-management, clinical, and public-safety function as illicit and nonmedical drug use evolves toward highly potent synthetic substances, polysubstance exposure, and region-specific drug trends. According to the UNODC World Drug Report 2024, an estimated 292 million people used drugs in 2022, up roughly 20% over the previous decade, while about 64 million people were living with drug use disorders. These conditions are increasing demand for reliable toxicology testing across hospitals, diagnostic laboratories, forensic agencies, correctional systems, treatment centers, and regulated workplaces.

The drug of abuse testing market is shaped by a dual requirement: fast screening and defensible confirmation. Immunoassay-based urine drug testing remains widely used for high-throughput screening, while liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry support confirmatory testing for complex analytes such as fentanyl analogs, benzodiazepines, synthetic cannabinoids, amphetamines, cocaine metabolites, and emerging novel psychoactive substances. Oral fluid, hair, and point-of-care drug testing are gaining relevance where observed collection, recent-use detection, and rapid decisions are operational priorities.

For industry leaders, growth is tied to clinical validity, chain-of-custody integrity, regulatory compliance, laboratory automation, and the ability to update test menus as drug supply patterns change. SEO-critical themes defining this market include drug of abuse testing, workplace drug testing, clinical toxicology, forensic toxicology, urine drug testing, oral fluid drug testing, fentanyl testing, confirmatory drug testing, and point-of-care toxicology testing.

Transformative Shifts in Drug Testing

The drug testing landscape is undergoing structural change as synthetic opioids, designer benzodiazepines, xylazine-adulterated substances, and rapidly changing cannabinoid products challenge legacy panel designs. In the United States, the CDC has identified synthetic opioids, primarily illicitly manufactured fentanyl, as the leading driver of overdose mortality in recent years. This has pushed laboratories and public-health programs to expand beyond traditional five-panel and ten-panel drug testing toward broader, more sensitive, and frequently updated assays.

A second shift is the movement from purely punitive testing to risk-based, clinically informed testing. Employers, health systems, treatment providers, and courts increasingly require results that can distinguish prescribed therapy from misuse, recent exposure from historical use, and screening presumptive positives from confirmed positives. This is accelerating adoption of confirmatory mass spectrometry, laboratory information management systems, and digitally traceable chain-of-custody workflows.

Testing matrices are also changing. Urine remains widely used because of cost, detection window, and established regulatory workflows, but oral fluid testing is expanding where collection observation and recent-use relevance matter. Hair testing continues to serve longer detection windows, especially in forensic and compliance contexts. The shift is not replacement; it is segmentation, with test type selected according to use case, analyte, legal defensibility, turnaround time, and budget.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value in drug of abuse testing by improving operational efficiency, analytical interpretation, and surveillance intelligence rather than replacing validated toxicology science. In high-volume laboratories, AI-enabled workflow tools can support specimen routing, instrument scheduling, quality-control review, and anomaly detection, helping reduce manual bottlenecks in environments where turnaround time is commercially and clinically important.

AI also strengthens interpretation when used under expert oversight. Machine learning can assist with chromatographic peak review, flag potential interferences, identify unusual metabolite patterns, and prioritize samples requiring toxicologist review. These capabilities are especially relevant for fentanyl analogs, synthetic cannabinoids, designer stimulants, nitazenes, and other novel psychoactive substances that may appear before standardized testing guidance is widely adopted.

The greatest strategic impact comes from connecting toxicology data with epidemiology, prescription monitoring, emergency department trends, and wastewater surveillance. When governed appropriately, AI can help detect emerging drug threats faster, guide test-menu updates, and improve operational planning for laboratories and point-of-care suppliers. However, adoption must remain anchored in validation, auditability, data privacy, bias control, and compliance with clinical laboratory and forensic quality standards.

Key Regional Insights for Drug Testing

Asia-Pacific is experiencing rising demand for drug of abuse testing as large population bases, expanding private diagnostics networks, and stricter transportation, workplace, and border-control programs increase screening volumes. China, India, Japan, South Korea, and Australia represent distinct demand centers, with adoption shaped by urbanization, law-enforcement modernization, roadside safety programs, and broader access to advanced laboratory infrastructure. The region also faces documented trafficking and use concerns around methamphetamine and synthetic drugs, making adaptable toxicology panels and confirmatory testing increasingly relevant.

North America remains one of the most mature regions for workplace drug testing, clinical toxicology, and forensic toxicology. The United States drives demand through employer programs, opioid-use disorder treatment monitoring, pain-management compliance, criminal justice testing, and public-health surveillance, while Canada's regulated cannabis environment and opioid crisis response sustain investment in laboratory and harm-reduction-linked testing. Latin America shows increasing adoption through workplace safety programs in mining, logistics, oil and gas, aviation, and law enforcement. Brazil and Mexico are central markets due to their industrial scale, expanding diagnostics networks, and cross-border drug-trafficking pressures.

Europe emphasizes harmonized quality, workplace safety, forensic reliability, and clinical toxicology capacity, with strong demand across Germany, France, Italy, Spain, and the United Kingdom. The Middle East, led by GCC countries, prioritizes strict drug-control policies, border security, aviation safety, and expatriate workforce screening. Africa remains an emerging market where demand is linked to public-sector capacity building, transport safety, occupational health, urban healthcare expansion, and the need for stronger surveillance systems to track changing drug-use patterns.

Key Economic and Strategic Group Insights

ASEAN demand is supported by expanding manufacturing, logistics, ports, and aviation sectors, where occupational safety and compliance testing are increasingly important. Countries in the region also face evolving synthetic drug trafficking patterns, including methamphetamine-related pressures reported by international drug-control agencies, making flexible test menus, rapid screening technologies, and confirmatory laboratory access strategically relevant.

The GCC is characterized by strict drug-control enforcement, high reliance on expatriate labor, and significant investment in healthcare and border-security infrastructure. These factors create demand for high-integrity testing systems, chain-of-custody controls, and confirmatory laboratory services. The European Union places strong emphasis on quality systems, privacy compliance, workplace health, and forensic defensibility, supporting demand for accredited laboratories, validated methods, and advanced mass spectrometry across clinical and forensic toxicology settings.

BRICS countries represent high-volume opportunity due to population scale, expanding diagnostics access, public-sector drug-control priorities, and industrial safety requirements across China, India, Brazil, Russia, and South Africa. G7 markets are more mature, with demand driven by clinical toxicology, opioid and polysubstance monitoring, road safety, cannabis policy variation, and regulated workplace programs. NATO countries add defense, security-clearance, transportation, and readiness-related testing requirements, making reliability, standardization, chain-of-custody integrity, and data security central procurement considerations.

Key Country Insights for Drug Testing

The United States is the most diversified drug of abuse testing market, supported by workplace programs, opioid-response initiatives, criminal justice testing, treatment monitoring, emergency care, and a broad network of certified laboratories. Canada's market is shaped by workplace safety, cannabis legalization, opioid-related public-health needs, and demand for oral fluid and confirmatory testing. Mexico and Brazil are important Latin American growth markets, with demand linked to transportation, industrial safety, law enforcement, cross-border drug-control priorities, and expanding private diagnostic capacity.

The United Kingdom combines workplace testing, clinical toxicology, road safety, and forensic demand, while Germany, France, Italy, and Spain benefit from established healthcare systems, accredited laboratories, occupational safety frameworks, and demand for legally defensible confirmatory testing. Russia's market is influenced by public-sector testing, forensic applications, workplace compliance, and drug-control enforcement priorities.

China and India represent scale-driven opportunities as diagnostics infrastructure expands and government focus on drug control remains strong. Japan emphasizes high-quality laboratory standards, workplace compliance, and precision in confirmatory testing, while Australia has a mature workplace and roadside testing environment, particularly in mining, transportation, and public safety. South Korea's demand is increasing with stronger enforcement attention, healthcare modernization, and growing awareness of emerging drug risks, including concerns around synthetic drugs and misuse of controlled substances.

Actionable Recommendations for Industry Leaders

Industry leaders should build adaptive test menus that include fentanyl, fentanyl analogs, buprenorphine, methadone, tramadol, benzodiazepines, synthetic cannabinoids, amphetamines, cocaine metabolites, cannabis markers, nitazenes, xylazine where regionally relevant, and locally prevalent novel psychoactive substances. Static panels are less effective in a market where drug supplies shift rapidly.

Organizations should pair rapid screening with confirmatory testing strategies that match the legal, clinical, or employment consequence of the result. Investment in LC-MS/MS capacity, validated oral fluid workflows, digital chain-of-custody systems, quality-management controls, and laboratory automation can improve defensibility and turnaround time.

Commercial teams should segment offerings by use case: workplace safety, treatment monitoring, forensic testing, emergency care, correctional programs, roadside testing, and public-health surveillance. Leaders that combine scientific rigor, regulatory awareness, AI-enabled operations, and region-specific market access will be best positioned for durable growth.

Research Methodology

This executive summary is developed using a structured secondary and analytical research approach based on verified public-health, regulatory, scientific, and industry sources. Key references include global drug-use evidence from the UNODC World Drug Report 2024, overdose surveillance from the U.S. CDC, national substance-use reporting from government health agencies, and testing guidance from recognized workplace, clinical, and forensic authorities.

The methodology applies data triangulation across epidemiology, regulatory frameworks, laboratory practice, technology adoption, and end-user demand. Market interpretation considers testing matrix, analyte class, application area, geography, and buyer type. Insights are reviewed for consistency with established toxicology practice, including presumptive screening, confirmatory testing, chain-of-custody requirements, laboratory accreditation, and quality-management standards.

No unsupported market-size, market-share, or forecasting claims are used. Emphasis is placed on verifiable trends, observed demand drivers, regulatory context, and technology adoption patterns that affect the drug of abuse testing market.

Conclusion

Drug of abuse testing is shifting from a standardized compliance function to a dynamic, data-driven toxicology ecosystem. Rising global drug use, synthetic opioid risks, cannabis policy divergence, workplace safety requirements, and public-health surveillance needs are expanding demand across clinical, forensic, occupational, and public-safety settings.

The strongest opportunities will come from validated testing portfolios that combine rapid screening, confirmatory mass spectrometry, flexible specimen matrices, digital chain-of-custody controls, and AI-supported laboratory workflows. Organizations that anticipate emerging analytes, align with regional regulations, and maintain scientific defensibility will lead the next phase of growth in the global drug of abuse testing market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug of Abuse Testing Market, by Sample Type

• 7.1. Hair
• 7.2. Oral Fluid
• 7.3. Urine

8. Drug of Abuse Testing Market, by Test Technology

• 8.1. Chromatography
  • 8.1.1. Gc-Ms
  • 8.1.2. Lc-Ms
    • 8.1.2.1. Lc-Ms/Ms
    • 8.1.2.2. Lc-Qtof
• 8.2. Immunoassay

9. Drug of Abuse Testing Market, by Drug Panel

• 9.1. Customized Panel
• 9.2. Expanded Panel
• 9.3. Five Panel
• 9.4. Ten Panel

10. Drug of Abuse Testing Market, by End User

• 10.1. Clinical Laboratory
• 10.2. Correctional Facility
• 10.3. Forensic Laboratory
• 10.4. Hospital

11. Drug of Abuse Testing Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Drug of Abuse Testing Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Drug of Abuse Testing Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. AccuBioTech Co., Ltd.
• 15.3. American Bio Medica Corporation
• 15.4. Bio-Rad Laboratories, Inc.
• 15.5. Clinical Reference Laboratory, LLC
• 15.6. Cordant Health Solutions Inc.
• 15.7. Danaher Corporation
• 15.8. Dragerwerk AG & Co. KGaA
• 15.9. Express Diagnostics International Inc.
• 15.10. F. Hoffmann-La Roche Ltd.
• 15.11. Laboratory Corporation of America Holdings
• 15.12. LGC Group Holdings Ltd.
• 15.13. LifeLoc Technologies, Inc.
• 15.14. MP Biomedicals, LLC
• 15.15. Omega Laboratories, Inc.
• 15.16. OraSure Technologies, Inc.
• 15.17. Precision Diagnostics Inc.
• 15.18. Premier Biotech, Inc.
• 15.19. Psychemedics Corporation
• 15.20. Quest Diagnostics Incorporated
• 15.21. Randox Laboratories Ltd.
• 15.22. Siemens Healthineers AG
• 15.23. SureScreen Diagnostics Ltd.
• 15.24. Thermo Fisher Scientific Inc.
• 15.25. Wondfo Biotech Co., Ltd.